Sept. 9, 2024 Jeffrey Flier is the former dean of Harvard Medical School. One of the biopharma industry’s marvels of the 2020s has been the enormous medical and financial success of the GLP-1 class of drugs. But the path to commercialization of these therapies was far more complex than most understand, and some of the earliest history has never been presented. Beginning in 1988, I was part of what I believe was the earliest commercial effort to develop GLP-1 as a metabolic therapy. Despite extre...